Posted by Michael Wonder on 28 Mar 2017
Xeljanz (tofacitinib citrate) receives marketing authorisation in the European Union for the treatment of moderate to severe active rheumatoid arthritis
27 March 2017 - Approval provides people living with rheumatoid arthritis in the European Union with a new oral treatment option.
Pfizer announced today that the European Commission has approved Xeljanz (tofacitinib citrate) 5 mg twice daily oral tablets in combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs.
Xeljanz can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate.
Xeljanz belongs to a new class of therapies called Janus kinase inhibitors.
